BURLINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics ("Aldeyra"), a biotechnology company focused on the development of products to treat diseases where free aldehydes are thought to be important to the pathology, today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a price to the public of $8.00 per share. Aldeyra expects gross proceeds from the offering to be $12,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Aldeyra has granted the underwriters a 45-day option to purchase up to 225,000 additional shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Capital Market under the symbol "ALDX" on May 2, 2014 and the offering is expected to close on May 7, 2014, subject to customary closing conditions.
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
A registration statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") was declared effective on May 1, 2014.
The offering is being made by means of a prospectus. Copies of the prospectus may be obtained by contacting Aegis Capital Corp, Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, email: email@example.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra will begin clinical testing of NS2 in 2014 for the treatment of Sjogren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com